Richard Aranda
Chief Tech/Sci/R&D Officer bij GOSSAMER BIO, INC.
Vermogen: 234 583 $ op 31-03-2024
Actieve functies van Richard Aranda
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01-06-2021 | - |
| Corporate Officer/Principal | - | 01-06-2021 |
Loopbaan van Richard Aranda
Eerdere bekende functies van Richard Aranda
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| RECEPTOS INC | Corporate Officer/Principal | 01-01-2015 | 01-01-2018 |
| Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01-01-2011 | 01-01-2015 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-08-2001 | 01-05-2011 |
Opleiding van Richard Aranda
| University of California, Santa Cruz | Undergraduate Degree |
| Stanford School of Medicine | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
| Novo-Nordisk Biochem, Inc. |
- Beurs
- Insiders
- Richard Aranda
- Ervaring
